Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
Ovarian cancer is a prevalent gynecologic malignancy with the second-highest mortality rate among gynecologic malignancies. Platinum-based chemotherapy is the first-line treatment for ovarian cancer; however, a majority of patients with ovarian cancer experience relapse and develop platinum resistance followi...
platinum resistancerecurrent ovarian cancerPlatinum-resistant recurrent ovarian cancer has a poor prognosis, but combined therapy with bevacizumab and anticancer agents may be useful. We report a patient with long-term disease control by the combination of bevacizumab and gemcitabine (BEV+GEM). The ...
Epithelial ovarian cancer is the most lethal gynaecological cancer worldwide. Chemotherapy resistance represents a significant clinical challenge and is the main reason for poor ovarian cancer prognosis. We identified novel expression of markers related to epithelial mesenchymal transitions (EMT) in a carbo...
The randomized, double-blind, multicenter SCORES trial enrolled patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease progressed on or after platinum-based chemotherapy; who received 1 or fewer lines of systemic therapy for ovarian cancer after platinum resistance; ...
Christina Buschmann1, Susanne Beyer1, Thomas Kolben1, Fabian Kraus1, Anca Chelariu‑Raicu1, Alexander Burges1, Sven Mahner1, Udo Jeschke1,3, Fabian Trillsch1 & Bastian Czogalla1* In recurrent epithelial ovarian cancer (EOC) most patients develop platinum-resistance. ...
making decisions about how do you treat a patient with platinum-sensitive ovarian cancer in terms of the choice of chemotherapy, and also whether or not to use maintenance treatment. Joyce, do you want to just give us a few points about these two questions? DR. LIU: Yeah, so I t...
We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer prior to additional platinum therapy. All patients were treated between July 1, 1997, and June 30, 2001. Platinum resistance was defined as less ...
it can lead to therapy resistance and induce the epithelial mesenchymal transition, lead study author Katherine Fuh, MD, PhD, assistant professor in Obstetrics and Gynecology at the Washington University School of Medicine and surgeon in Gynecologic Oncology at Siteman Cancer Center, said during a pre...
This case report supports the prospective evaluation of alternative therapies such as these in patients with platinum-refractory ovarian cancer. 展开 关键词: Ovarian cancer Platinum-resistance Alternative therapies Genistein DOI: 10.1016/j.ygyno.2005.08.006 被引量: 37 ...